Shots:

• Exscientia to receive $20M as an option exercise fee and is eligible for development milestones along with royalties on any product sales
• BMS has elected to in-license an Exscientia’s immune-modulating drug candidate & will be responsible for clinical and commercial development of the product
• In May’21- the companies have expanded the collaboration to accelerate the discovery of drug candidates by using Exscientia’s AI technology for multiple therapeutic areas- including oncology and immunology

  Ref: Exscientia | Image: BMS